Heart Failure Testing Market

By Test Type;

Electrocardiogram, Blood Test, B-type natriuretic peptide (BNP), ProBNP, NT-ProBNP, Atrial Natriuretic Peptide, and Others

By Product Type;

Instruments, Regents, and POC Testing Kits

By Delivery Mode;

Web-Based, On-Premises, Cloud-Based Systems

By Features;

Heart Monitoring Activity, Tracking Periodic Tests, Review Progress, Diary Management Tool, Diagnosis, and Therapy Monitoring, Others

By End Users;

Hospitals, Ambulatory Surgical Centers, Diagnostic Laboratories, Diagnostic Imaging Centers, and Cardiac Care Centers

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn119843553 Published Date: June, 2025 Updated Date: July, 2025

Heart Failure Testing Market Overview

Heart Failure Testing Market (USD Million)

Heart Failure Testing Market was valued at USD 1077.97 million in the year 2024. The size of this market is expected to increase to USD 1730.99 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 7.0%.


Heart Failure Testing Market

*Market size in USD million

CAGR 7.0 %


Study Period2025 - 2031
Base Year2024
CAGR (%)7.0 %
Market Size (2024)USD 1077.97 Million
Market Size (2031)USD 1730.99 Million
Market ConcentrationMedium
Report Pages371
1077.97
2024
1730.99
2031

Major Players

  • Abbott Laboratories
  • Response Biomedical
  • F. Hoffmann-La Roche AG
  • Trinity Biotech plc
  • Quidel Corporation
  • Siemens Healthcare GmbH
  • bioMrieux SA
  • Koninklijke Philips N.V

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Heart Failure Testing Market

Fragmented - Highly competitive market without dominant players


The Heart Failure Testing Market is witnessing notable growth due to the increasing focus on early-stage identification of cardiac complications. With over 60% of healthcare institutions incorporating specialized heart function assessments, there is a clear shift toward preventive care. This evolution is fostering opportunities for growth as demand for reliable and timely diagnostics continues to escalate. Investments in scalable diagnostic solutions are becoming integral to strategies for expansion and quality care delivery.

Innovation Driving Clinical Advancements
The market is being transformed by technological advancements in biomarkers, imaging, and multi-parametric diagnostics. Innovations are driving the adoption of testing systems that offer high accuracy, with over 55% of facilities preferring integrated solutions. These tools are enabling more precise diagnosis, improving treatment planning and driving the evolution of future outlook in cardiac diagnostics. Companies are aligning with innovation-focused strategies to maintain a competitive edge.

Emerging Opportunities and Clinical Integration
There is a growing emphasis on integrating heart failure testing into broader clinical pathways, with around 58% of institutions incorporating diagnostics into routine care. This integration presents new opportunities for test developers to align with value-based care trends. Health systems are adopting strategies that enhance efficiency, reduce readmission risks, and improve patient outcomes—all of which fuel the need for advanced heart failure diagnostics.

Outlook for Market Expansion and Innovation
The future of the Heart Failure Testing Market is marked by robust expansion plans focused on accessibility, affordability, and automation. With testing demand projected to grow across over 65% of diagnostic labs, stakeholders are prioritizing innovation in portable and rapid testing platforms. This trend underscores a promising growth trajectory supported by strategic investment in R&D, paving the way for technological innovations that improve diagnostic value and reliability.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Test Type
    2. Market Snapshot, By Product Type
    3. Market Snapshot, By Delivery Mode
    4. Market Snapshot, By Features
    5. Market Snapshot, By End Users
    6. Market Snapshot, By Region
  4. Heart Failure Testing Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Aging Population
        2. Technological Advancements
        3. Rising Incidence of Cardiovascular Diseases
      2. Restraints
        1. High Costs of Advanced Testing
        2. Limited Awareness and Screening Programs
        3. Regulatory and Reimbursement Challenges
      3. Opportunities
        1. Expansion in Emerging Markets
        2. Personalized Medicine and Biomarkers
        3. Integration of AI and Big Data
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Heart Failure Testing Market, By Test Type, 2021 - 2031 (USD Million)
      1. Electrocardiogram
      2. Blood Test
      3. B-type natriuretic peptide (BNP)
      4. ProBNP
      5. NT-ProBNP
      6. Atrial Natriuretic Peptide
      7. Others
    2. Heart Failure Testing Market, By Product Type, 2021 - 2031 (USD Million)
      1. Instruments
      2. Regents
      3. POC Testing Kits
    3. Heart Failure Testing Market, By Delivery Mode, 2021 - 2031 (USD Million)
      1. Web-Based
      2. On-Premises
      3. Cloud-Based Systems
    4. Heart Failure Testing Market, By Features, 2021 - 2031 (USD Million)
      1. Heart Monitoring Activity
      2. Tracking Periodic Tests
      3. Review Progress
      4. Diary Management Tool
      5. Diagnosis
      6. Therapy Monitoring
      7. Others
    5. Heart Failure Testing Market, By End Users, 2021 - 2031 (USD Million)
      1. Hospitals
      2. Ambulatory Surgical Centers
      3. Diagnostic Laboratories
      4. Diagnostic Imaging Centers
      5. Cardiac Care Centers
    6. Heart Failure Testing Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Abbott Laboratories
      2. Response Biomedical
      3. F. Hoffmann-La Roche AG
      4. Trinity Biotech plc
      5. Quidel Corporation
      6. Siemens Healthcare GmbH
      7. bioMrieux SA
      8. Koninklijke Philips N.V
  7. Analyst Views
  8. Future Outlook of the Market